Literature DB >> 21960184

Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis.

Wei An1, Yu Bai, Shang-Xin Deng, Jie Gao, Qi-Wen Ben, Quan-Cai Cai, Hua-Gao Zhang, Zhao-Shen Li.   

Abstract

Inconsistent results with regard to adiponectin levels in patients with colorectal cancer (CRC) and adenoma have been reported. To evaluate adiponectin levels in patients with CRC and adenoma, a meta-analysis on studies which compared adiponectin levels in patients with CRC or adenoma with healthy controls was carried out. A literature search was performed through Pubmed, EMBASE, and Science Citation Index Expanded database. Pooled-weighted mean differences and 95% confidence intervals (95%CI) were calculated by using random-effects models. Heterogeneity between studies was assessed using the Cochran's Q and I statistics. A total of 13 studies were identified, which included 2632 cases of CRC or adenoma and 2753 healthy controls. Adiponectin levels were significantly lower in patients with CRC or adenoma compared with healthy controls, with significant heterogeneity [weighted mean differences of -1.51 (95% CI: -2.42 to -0.59; Pheterogeneity<0.001) for CRC and -1.29 (95% CI: -2.01to -0.58; Pheterogeneity<0.001) for colorectal adenoma, respectively]. On stratified analysis of CRC, significant difference in adiponectin levels between patients with CRC and healthy controls was reported only in case-control studies or small sample size studies (n<100), but not in nested case-control studies or large sample size studies (n≥100). In addition, metaregression analysis indicated that study design and sample size partly contributed to the significant heterogeneity (P=0.022 for study design and P=0.018 for sample size, respectively). For colorectal adenoma studies, stratified analysis indicated that sample size was one of the heterogeneous factors. Sensitivity analysis showed that there were no changes in the direction of effect when any one study was excluded. No publication bias was detected. Adiponectin levels are lower in patients with CRC or colorectal adenoma compared with those in healthy controls. Future studies are warranted to clarify the association of adiponectin levels and carcinogenesis of the colorectum.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21960184     DOI: 10.1097/CEJ.0b013e32834c9b55

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  37 in total

1.  Total and high-molecular weight adiponectin and risk of colorectal cancer: the European Prospective Investigation into Cancer and Nutrition Study.

Authors:  Krasimira Aleksandrova; Heiner Boeing; Mazda Jenab; H Bas Bueno-de-Mesquita; Eugene Jansen; Fränzel J B van Duijnhoven; Veronika Fedirko; Sabina Rinaldi; Isabelle Romieu; Elio Riboli; Dora Romaguera; Sabine Westphal; Kim Overvad; Anne Tjønneland; Marie Christine Boutron-Ruault; Françoise Clavel-Chapelon; Rudolf Kaaks; Annekatrin Lukanova; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Claudia Agnoli; Amalia Mattiello; Calogero Saieva; Paolo Vineis; Rosario Tumino; Petra H Peeters; Marcial Argüelles; Catalina Bonet; María-José Sánchez; Miren Dorronsoro; Jose-María Huerta; Aurelio Barricarte; Richard Palmqvist; Göran Hallmans; Kay-Tee Khaw; Nick Wareham; Naomi E Allen; Francesca L Crowe; Tobias Pischon
Journal:  Carcinogenesis       Date:  2012-03-19       Impact factor: 4.944

2.  Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study.

Authors:  Xian-Feng Lin; Ke-Qing Shi; Jie You; Wen-Yue Liu; Ying-Wan Luo; Fa-Ling Wu; Yong-Ping Chen; Danny Ka-Ho Wong; Man-Fung Yuen; Ming-Hua Zheng
Journal:  Mol Biol Rep       Date:  2014-01-22       Impact factor: 2.316

3.  Association between plasma adiponectin levels and colorectal cancer risk in women.

Authors:  Paulette D Chandler; Julie E Buring; JoAnn E Manson; M V Moorthy; Shumin Zhang; I-Min Lee; Jennifer H Lin
Journal:  Cancer Causes Control       Date:  2015-05-05       Impact factor: 2.506

4.  Adiponectin (ADIPOQ) rs2241766 G/T polymorphism is associated with risk of cancer: evidence from a meta-analysis.

Authors:  Wei Zhou; Yi Liu; De-Wu Zhong
Journal:  Tumour Biol       Date:  2012-11-11

5.  Association of variants on ADIPOQ and AdipoR1 and the prognosis of gastric cancer patients after gastrectomy treatment.

Authors:  Xuming Wu; Peizhan Chen; Yiyi Ou; Jibin Liu; Chenglin Li; Hui Wang; Fulin Qiang
Journal:  Mol Biol Rep       Date:  2014-10-01       Impact factor: 2.316

Review 6.  Obesity and cholangiocarcinoma.

Authors:  Mansour A Parsi
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

7.  Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer.

Authors:  Dawn Q Chong; Raaj S Mehta; Mingyang Song; Dmitriy Kedrin; Jeffrey A Meyerhardt; Kimmie Ng; Kana Wu; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino; Andrew T Chan
Journal:  Cancer Prev Res (Phila)       Date:  2015-09-17

Review 8.  Insights into the Link Between Obesity and Cancer.

Authors:  Sarah E Ackerman; Olivia A Blackburn; François Marchildon; Paul Cohen
Journal:  Curr Obes Rep       Date:  2017-06

9.  Three adiponectin rs1501299G/T, rs822395A/C, and rs822396A/G polymorphisms and risk of cancer development: a meta-analysis.

Authors:  Hui-Jie Fan; Zheng-Fang Wen; Ben-Ling Xu; Jing-Jing Wu; Yong-Xu Jia; Ming Gao; Ming-Jun Li; Yan-Ru Qin
Journal:  Tumour Biol       Date:  2012-12-09

Review 10.  Mechanisms linking obesity and cancer.

Authors:  Sharon M Louie; Lindsay S Roberts; Daniel K Nomura
Journal:  Biochim Biophys Acta       Date:  2013-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.